“[Cost-Utility Analysis of Dupilumab for the Treatment of Severe Atopic Dermatitis in Children and Adolescents in Italy]” (2022) Farmeconomia. Health economics and therapeutic pathways, 23(1). doi:10.7175/fe.v23i1.1527.